IDYA
Price
$22.18
Change
-$0.54 (-2.38%)
Updated
Jan 17 closing price
Capitalization
1.92B
72 days until earnings call
RGLS
Price
$1.24
Change
-$0.04 (-3.12%)
Updated
Jan 17 closing price
Capitalization
81.22M
60 days until earnings call
Ad is loading...

IDYA vs RGLS

Header iconIDYA vs RGLS Comparison
Open Charts IDYA vs RGLSBanner chart's image
IDEAYA Biosciences
Price$22.18
Change-$0.54 (-2.38%)
Volume$528.55K
Capitalization1.92B
Regulus Therapeutics
Price$1.24
Change-$0.04 (-3.12%)
Volume$330.14K
Capitalization81.22M
IDYA vs RGLS Comparison Chart
Loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IDYA vs. RGLS commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Hold and RGLS is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (IDYA: $22.18 vs. RGLS: $1.24)
Brand notoriety: IDYA and RGLS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 55% vs. RGLS: 114%
Market capitalization -- IDYA: $1.92B vs. RGLS: $81.22M
IDYA [@Biotechnology] is valued at $1.92B. RGLS’s [@Biotechnology] market capitalization is $81.22M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 0 FA rating(s) are green whileRGLS’s FA Score has 1 green FA rating(s).

  • IDYA’s FA Score: 0 green, 5 red.
  • RGLS’s FA Score: 1 green, 4 red.
According to our system of comparison, RGLS is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 2 TA indicator(s) are bullish while RGLS’s TA Score has 3 bullish TA indicator(s).

  • IDYA’s TA Score: 2 bullish, 3 bearish.
  • RGLS’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, RGLS is a better buy in the short-term than IDYA.

Price Growth

IDYA (@Biotechnology) experienced а -7.70% price change this week, while RGLS (@Biotechnology) price change was -12.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

IDYA is expected to report earnings on May 13, 2025.

RGLS is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($1.92B) has a higher market cap than RGLS($81.2M). IDYA YTD gains are higher at: -13.696 vs. RGLS (-21.519). RGLS has higher annual earnings (EBITDA): -41.03M vs. IDYA (-220.54M). IDYA has more cash in the bank: 920M vs. RGLS (87.3M). RGLS has less debt than IDYA: RGLS (476K) vs IDYA (18.8M). IDYA has higher revenues than RGLS: IDYA (3.92M) vs RGLS (0).
IDYARGLSIDYA / RGLS
Capitalization1.92B81.2M2,361%
EBITDA-220.54M-41.03M537%
Gain YTD-13.696-21.51964%
P/E RatioN/AN/A-
Revenue3.92M0-
Total Cash920M87.3M1,054%
Total Debt18.8M476K3,950%
FUNDAMENTALS RATINGS
RGLS: Fundamental Ratings
RGLS
OUTLOOK RATING
1..100
58
VALUATION
overvalued / fair valued / undervalued
1..100
20
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
64
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
IDYARGLS
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 12 days ago
74%
Bullish Trend 12 days ago
88%
Momentum
ODDS (%)
Bearish Trend 12 days ago
84%
Bearish Trend 12 days ago
87%
MACD
ODDS (%)
Bullish Trend 12 days ago
85%
N/A
TrendWeek
ODDS (%)
Bearish Trend 12 days ago
78%
Bearish Trend 12 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 12 days ago
82%
Bearish Trend 12 days ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 25 days ago
85%
Declines
ODDS (%)
Bearish Trend 12 days ago
76%
Bearish Trend 12 days ago
90%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 12 days ago
80%
Bullish Trend 12 days ago
87%
View a ticker or compare two or three
Ad is loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AMKR25.910.45
+1.77%
Amkor Technology
CYH3.060.05
+1.66%
Community Health Systems
WIMI1.110.01
+0.45%
WiMi Hologram Cloud
AMRX8.26-0.05
-0.60%
Amneal Pharmaceuticals
MRK97.92-2.78
-2.76%
Merck & Co

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with GRI. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then GRI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-2.38%
GRI - IDYA
54%
Loosely correlated
+2.11%
PLRX - IDYA
48%
Loosely correlated
-3.36%
ETNB - IDYA
47%
Loosely correlated
+3.53%
RCKT - IDYA
47%
Loosely correlated
+0.98%
PRME - IDYA
47%
Loosely correlated
+0.70%
More

RGLS and

Correlation & Price change

A.I.dvisor tells us that RGLS and SPRY have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RGLS and SPRY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGLS
1D Price
Change %
RGLS100%
-3.12%
SPRY - RGLS
28%
Poorly correlated
+3.20%
NAUT - RGLS
26%
Poorly correlated
+1.58%
FENC - RGLS
25%
Poorly correlated
-1.60%
IDYA - RGLS
25%
Poorly correlated
-2.38%
CARA - RGLS
25%
Poorly correlated
+1.09%
More